---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211934"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:06:50.817243+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU

## Summary
- Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.
- EVO756 Phase 2b top-line data in chronic spontaneous urticaria expected June 2026; atopic dermatitis data in Q3 2026.
- Phase 2b dose-ranging trial for EVO756 in migraine prophylaxis to start mid-2026; top-line data anticipated in 2027.
- EVO301 Phase 2b atopic dermatitis trial planned for mid-2027 after positive Phase 2a proof-of-concept data in February 2026.
- Revenue zero vs $3.0M prior year (Maruho collaboration ended); R&D expenses $17.3M, G&A $6.6M.

## SEC filing metadata
- accession: 0001193125-26-211934
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526211934/0001193125-26-211934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526211934/evmn-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211934
- JSON: https://secwatch.observer/filing/0001193125-26-211934.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211934.txt

## Source-grounded claims
- claim_id: f7afe33de33985a4c1b1b7a48371c157956c9a06
  claim: Evommune, Inc. reported first quarter ended March 31, 2026 results: revenue zero.
  evidence_excerpt: Revenue was zero for the first quarter ended March 31, 2026, compared to $3.0 million for the same period in 2025, attributable to the Company’s strategic collaboration with Maruho related to licensing EVO756 in Japan.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2044725/000119312526211934/0001193125-26-211934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.